Drug Index


Synonyms :

25-hydroxycholecalciferol, 25-hydroxyvitamin D3, Calcidiol, Calcifediol

Mechanism :

It is a vitamin D derivative.
Natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin D3 (cholecalciferol). Vitamin D3 is then activated in the liver and the kidney before it is fully active at target tissues.

Indication :

  • Treatment and prophylaxis of renal osteodystrophy & cholestatic liver disease
  • Vitamin D deficiency in liver patients
  • Hypophosphatemic rickets
  • Neonatal hypocalcemia

Contraindications :

Should not be given to patients with hypercalcemia or evidence of vitamin D toxicity. Also avoid in patients with hypersensitivity to propylene glycol and in premature infants.

Dosing :

0.25 mcg or 0.50 mcg capsules.
Prophylaxis against early neonatal hypocalcaemia in premature babies: Oral
0.1 mcg/kg/day.
Neonatal hypocalcemia: Oral
Initially 0.05-0.1 mcg/kg OD then modify according to response. (Max: 2 mcg/day).
Hypophosphatemic rickets: Oral
Neonates and premature infants: 0.05-0.1 mcg/kg/day.
<20 kg: 0.05 mcg/kg/day.
>20 kg: 1 mcg/day.
Vitamin D deficiency in liver patients: Oral
0.05-0.1 mcg/kg/dose OD (Max starting dose 1 mcg). Then adjust dose according to levels.
Treatment and prophylaxis of renal osteodystrophy & cholestatic liver disease: Oral
<20 kg: 0.015-0.03 mcg/kg OD. Max: 0.5 mcg.
>20 kg: 0.25-0.5 mcg OD.
Adjust dose according to response.

Adverse Effect :

Hypercalcemia syndrome, weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain, abdominal pain, polyuria, polydipsia, anorexia, weight loss, nocturia, conjunctivitis (calcific), pancreatitis, photophobia, rhinorrhea, pruritus, hyperthermia, decreased libido, elevated BUN, albuminuria, hypercholesterolemia, elevated AST/ALT, ectopic calcification, nephrocalcinosis, hypertension, cardiac arrhythmias.

Interaction :

Cholestyramine: Reduces intestinal absorption of alfacalcidol.
Phenytoin/Phenobarbital: May reduce endogenous plasma levels of 25(OH)D3 by accelerating metabolism.
Thiazides: Concomitant administration of thiazides causes hypercalcemia.
Digitalis: Hypercalcemia in such patients may precipitate cardiac arrhythmias.
Ketoconazole: May inhibit both synthetic and catabolic enzymes of calcitriol.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDNot dialysed. Dose as in normal renal function
HDDialysed. Dose as in normal renal function
HDF/High fluxDialysed. Dose as in normal renal function
CAV/VVHDNot dialysed. Dose as in normal renal function

Hepatic Dose :

No dosage adjustments are recommended.
03/18/2024 21:59:37 Alfacalcidol
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0